Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Resonance Specialties's interest expense for the
three
months ended in Jun. 2026 was ₹ -0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-2 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Resonance Specialties Ltd has enough cash to cover all of its debt. Its financial situation is stable.
Resonance Specialties Interest Expense Historical Data
* Premium members only.
The historical data trend for Resonance Specialties's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Specialties (BOM:524218) has a Interest Expense of ₹-2 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Resonance Specialties and its competitors.
Is Resonance Specialties' Interest Expense too high?
Resonance Specialties' current Interest Expense is ₹-2 Mil. Overall, Resonance Specialties has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Resonance Specialties' Interest Expense compare to DOW?
Resonance Specialties' Interest Expense of ₹-2 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Chemicals company?
A good Interest Expense depends on the Chemicals industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Resonance Specialties and its competitors. Resonance Specialties's current Interest Expense is ₹-2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Specialties stock overvalued right now?
Based on GuruFocus' analysis, Resonance Specialties (BOM:524218) is currently considered Fairly Valued. The stock's GF Value™ is ₹158.20, compared to a current price of ₹173.05 — trading 9.4% above its estimated fair value. The current Interest Expense is ₹-2 Mil. Resonance Specialties' overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Resonance Specialties (BOM:524218), the current Interest Expense is ₹-2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Resonance Specialties (BOM:524218) Overvalued in 2026?
Based on GuruFocus' analysis, Resonance Specialties stock appears to be overvalued.
The current stock price of ₹173.05 is trading 9.4% above its estimated GF Value™ of ₹158.20.
GuruFocus considers Resonance Specialties to be Fairly Valued.
Key valuation signals for BOM:524218:
Interest Expense: ₹-2 Mil
GF Value™: ₹158.20 vs. price of ₹173.05 (9.4% above fair value)
No single metric tells the full story. See the BOM:524218 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Resonance Specialties Ltd is engaged in the manufacturing of chemicals. The company is manufacturing Pyridine, Picoline, Cynopyridine, and derivatives of the same. Bulk drugs and nutritional products are tolls converted. It delivers pyridine and related products. The company has only one segment which is Chemical Manufacturing. The company also manufactures anti-tuberculosis products such as Isoniazid. Geographically. It operates in India and Outside India. The majority of segment revenue is from Outside India.
71GF Score
Get the complete analysis for BOM:524218
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524218 has been successfully added to your 
